CompanyGraph
Colgate-Palmolive Co
CL · NYSE Arca · United States
Sells government-approved fluoride toothpaste in 58 countries and prescription pet food that vets must authorize.
Colgate-Palmolive sells fluoride toothpaste across 58 countries and prescription pet food through veterinary practices, and both businesses are built around the same underlying logic: regulatory approval and embedded relationships that take years to accumulate and cannot be bought outright. On the toothpaste side, each country sets its own permitted fluoride concentration, so every national formulation — a fixed ratio of sodium fluoride, calcium carbonate, and hydrated silica — is a separate regulatory object that must clear its own approval cycle before a single tube can be sold, meaning the 58-country manufacturing footprint exists to hold those clearances, not just to cut shipping costs. On the pet food side, Hill's prescription diets for kidney disease or diabetes require a veterinarian's authorization to purchase, so the business depends on active relationships with roughly 25,000 vet practices worldwide, each maintained by a regional sales representative and reinforced by clinical research partnerships with veterinary schools that give individual vets a reason to recommend Hill's over a cheaper alternative. The risk in both cases is structural drift: if countries tighten fluoride rules or water fluoridation declines, demand for the core toothpaste formulations shrinks, and if veterinary consolidation into corporate chains shifts prescription decisions from individual practitioners to centralized purchasing committees, the person-to-practice relationship model that embeds Hill's in recommendation behavior stops fitting the channel it was built for.
How does this company make money?
The company earns money each time a tube of fluoride toothpaste or another oral care product is sold through retailers like Walmart. It also sells Hill's prescription pet diets through vet practices, and those products carry higher profit margins than standard retail items because they are medically specialized and not sold in ordinary stores.
What makes this company hard to replace?
Vet practices that use Hill's are already connected to its ordering platform and nutritional recommendation software — switching means rebuilding that integration with a different supplier. When a pet is on a therapeutic diet for kidney disease or diabetes, moving to a different brand requires veterinary supervision throughout the transition, which discourages switching simply by adding friction and medical risk. On the toothpaste side, any company trying to replace Hill's formulations in a new country would have to go through its own 12-to-24-month regulatory approval cycle before a single tube could be sold.
What limits this company?
Hill's prescription pet food can only reach new customers as fast as a sales representative can build a real working relationship with each vet practice. There is no shortcut — those 25,000 individual relationships cannot be handled by a website or a call center. That human-to-practice ceiling limits how quickly Hill's can grow, no matter how much product the factories can make.
What does this company depend on?
The company cannot operate without a reliable supply of sodium fluoride, calcium carbonate, and hydrated silica — the raw materials in every toothpaste formula. It also depends on the FDA and equivalent regulators in each country to grant and maintain fluoride concentration approvals, and on the network of roughly 25,000 veterinary practices worldwide that stock and authorize Hill's prescription diets. Specialized manufacturing equipment built for fluoride toothpaste production is also a necessary input that cannot easily be substituted.
Who depends on this company?
Vet practices around the world depend on Hill's to have therapeutic diet options to recommend when a pet is diagnosed with kidney disease or diabetes — without Hill's, those treatment pathways narrow. Walmart and other large retailers depend on toothpaste as a category that pulls shoppers into oral care aisles, and Hill's fluoride products drive much of that traffic. Consumers in emerging markets that account for 45% of the company's revenue often have no comparable local alternative, because no other fluoride toothpaste in those regions has gone through the regulatory approval process or built the distribution infrastructure.
How does this company scale?
Once the company earns a fluoride toothpaste approval in one country, the underlying formulation knowledge transfers to the next market — the chemistry is already understood, and the regulatory process becomes more familiar each time. That makes geographic expansion of toothpaste products faster once the first few markets are established. Hill's prescription pet food does not scale the same way: every new vet practice requires its own relationship, built by a person, over time. That part of the business grows slowly by design.
What external forces can significantly affect this company?
If cities and towns change their water fluoridation policies, consumers may feel less need for fluoride toothpaste, which would shrink demand for the company's core product. Veterinary industry consolidation into corporate chains is already shifting how prescription diet decisions get made, moving authority away from individual vets toward centralized buyers. Currency devaluation in the emerging markets that generate 45% of the company's revenue means those sales are worth less when converted back into US dollars, which directly reduces reported earnings.
Where is this company structurally vulnerable?
If large corporate chains keep buying up independent vet practices and move prescription diet decisions away from individual vets toward central purchasing committees, the whole model cracks. The company's strength is persuading individual veterinarians with clinical research and personal relationships. A committee negotiating across hundreds of locations cares more about price and margin than about the science one sales representative brought to one vet.